Metabolic modulators for chronic cardiac ischemia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 10, Issue 4, 2005, Pages 217-223

  Parang, Pirouz ^a   Singh, Bramah ^b   Arora, Rohit ^c,d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angina; Coronary heart disease; Ischemia

Indexed keywords

ACETYL COENZYME A; ACETYL COENZYME A ACYLTRANSFERASE; ADENOSINE TRIPHOSPHATE; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; DICHLOROACETIC ACID; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; FATTY ACID; GLUCOSE; GLYCERYL TRINITRATE; HEART ENZYME; HEPARIN; METOPROLOL; NIFEDIPINE; NITRATE; OXYGEN; PIPERAZINE DERIVATIVE; PROPIONYLCARNITINE; PROPRANOLOL; RANOLAZINE; RIBOSE; TRICARBOXYLIC ACID; TRIMETAZIDINE; UNINDEXED DRUG; VERAPAMIL;

ANGINA PECTORIS; ASTHENIA; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY BYPASS GRAFT; DIZZINESS; DRUG EFFICACY; ECHOCARDIOGRAPHY; EXERCISE TEST; FATTY ACID METABOLISM; GASTROINTESTINAL TOXICITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEMODYNAMICS; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANIMALS; CARNITINE; CHRONIC DISEASE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEART; HUMANS; LIPID METABOLISM; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; TRIMETAZIDINE; VASODILATOR AGENTS; VITAMIN B COMPLEX;

EID: 29344444996     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840501000402     Document Type: Review

References (29)

1. Chaitman BR, Pepine CJ, Parker JO, et al, Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 291:309-316, 2004
2. Hüter JF, Piper HM, Spieckermann PG. Effect of fatty acid oxidation on efficiency of energy production in rat heart. Am J Physiol 249(4 Pt 2):H723-728, 1985
3. Anderson JR, Khou S, Nawarkas JJ. Ranolazine. A potential new treatment for chronic stable angina. Heart Disease 3:264-269, 2001
4. Leong L, Horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur Heart J 25:634-641, 2004
5. Dyck J, Cheng J-F, Stanley W, et al. Malonyl coenzyme A decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94:e78-e84, 2004
6. McCormack JG, Stanley WC, Wolff AA. Ranolazine: A novel metabolic modulator for the treatment of angina. Gen Pharmac 30:639-645, 1998
7. Thadani U, Ezckowitz M, Fenney L, et al. Double blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 90:726-734, 1994
8. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmac 20:131-138, 1992
9. Rousseau MF, Visser FF, Bax JJ, et al. Ranolazine: Anti-anginal therapy with a novel mechanism: Controlled comparison versus atenolol. Eur Heart J 15:95, 1994
10. Chaitman BR, Skettino SL, Parker JO, et al. MARISA Investigators. Anti-ischemic effects and long term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43:1375-1382, 2004
11. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazadine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86:580-588, 2000
12. MacInnes A, Fairman DA, Binding P, et al. The anti-anginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 93:e26-e32, 2003
13. Lopaschuk GD, Barr R, Thomas PD, et al. Beneficial effects of trimetazadine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:e33-e37, 2003
14. Manchanda SC. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. Int J Cardiol 88:83-89, 2003
15. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazadine and metoprolol: Results of a randomized, double-blind, multi-centre study (TRIMPOL II) TRImetazaidine in POLand. Eur Heart J 22:2267-2274, 2001
16. Marzilli M, Klein W. Efficacy of tolerability of trimetazadine in stable angina: A meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 14:171-179, 2003
17. Fragasso G, Piatti PM, Monti L, et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease. Evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 39:413-419, 2002
18. Lango R, Smolenski RT, Narkiewicz M, et al. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res 51:21-29, 2001
19. Sethi R, Dhalla KS, Ganguly PK, et al. Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction. Cardiovasc Res 42:607-615, 1999
20. Felix C, Gillis M, Driedzic WR, et al. Effects of propionyl L-carnitine on isolated mitochondrial function in the reperfused diabetic rat hearts. Diabetes Clin Pract 53:17-24, 2001
21. Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: The L-Carnitine Ecocardiografia Digitalzzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol 26:380-387, 1995
22. Singh RB, Niaz MA, Agarwal P, et al. A randomized, double-blind, placebo-controlled trial of L-carnitine in suspected myocardial infarction. Postgrad Med J 72:45-50, 1996
23. Iyer RN, Khan AA, Gupta A, et al. L-carnitine moderately improves the exercise tolerance in chronic stable angina. J Assoc Physicians India 48:1050-1052, 2000
24. Pliml W, Von Arnim T, Stablein K, et al. Effects of ribose on exercise-induced ischemia in stable coronary artery disease. Lancet 340:507-510, 1992
25. Omran H, Illien S, MacCarter D, et al. D-ribose improves diastolic function and quality of life in congestive heart failure patients: A prospective feasibility study. Eur J Heart Fail 5:615-619, 2003
26. Kudej R, White L, Kudej A, et al. Brief increase in carbohydrate oxidation after reperfusion reverses myocardial stunning in conscious pigs. Circulation 106:2836-2841, 2002
27. Barak C, Reed M, Maniscalco S, et al. Effects of dichloroacetate on mechanical recovery and oxidation of physiologic substrates after ischemia and reperfusion in the isolated heart. J Cardiovasc Pharmacol 31:336-344, 1998
28. Wambolt R, Lopaschuk G, Browney R, et al. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol 36:1378-1385, 2000
29. Wargovich TJ, MacDonald RG, Hill JA, et al. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 61:65-70, 1988